KASRA KARAMLOU, M.D.

Plain English
This study looked at a new treatment, carfilzomib combined with R-CHOP, for patients with a type of lymphoma called non-germinal center diffuse large B-cell lymphoma. Out of 48 patients, 89% showed a positive response to the treatment, with 70% fully recovering. The treatment reduced the chances of disease progression and death significantly compared to the standard care, indicating it might be a better option for these patients. Who this helps: This helps patients with non-germinal center diffuse large B-cell lymphoma.

Plain English
This study examined a 61-year-old man with a genetic condition called neurofibromatosis type 1 (NF-1) who developed multiple gastrointestinal stromal tumors (GISTs). The patient suffered from severe anemia due to bleeding from these tumors, which were surgically removed. The findings highlight that in patients with NF-1, surgery is a necessary approach since other treatments, like targeted therapies, are not effective for their specific GISTs. Who this helps: This information benefits doctors and patients with NF-1 by guiding treatment options for GISTs.

Plain English
In this study, researchers tested a combination of two drugs, pracinostat and azacitidine, in older patients (65 years and older) with newly diagnosed acute myeloid leukemia (AML) who couldn't undergo standard chemotherapy. They found that 52% of the 50 patients treated experienced complete remission, and the average survival time was about 19 months. It’s important because it shows that this combination can be effective and is generally well-tolerated for a vulnerable group that often has limited treatment options. Who this helps: Older patients with newly diagnosed AML who are not eligible for standard treatments.

Plain English
Researchers looked at breast cancer patients who had lung nodules to see if they were actually dealing with a new lung cancer rather than just spreading breast cancer. They studied 54 patients over 10 years and found that while most were thought to have metastatic breast cancer, 21 actually had lung tumors that could be treated. This distinction matters because 9 of those patients underwent surgery that could potentially save their lives. Who this helps: Breast cancer patients with lung nodules and their doctors.

Plain English
This study looked at the side effects of two common treatments for breast cancer: tamoxifen and aromatase inhibitors (AIs). Of the 452 patients surveyed, 82% were on some form of hormonal therapy, with 54% taking tamoxifen and 46% using AIs. Both groups reported significant side effects, but AIs were associated with more joint pain, and 47.5% of AI users switched medications to find relief, compared to 37% of tamoxifen users. Who this helps: This research benefits breast cancer patients and their doctors by providing insight into treatment experiences and side effects.

Plain English
This study looked at a 54-year-old man who had severe skin and lung conditions related to Sweet syndrome and myelodysplastic disorder. After trying various treatments with little success, he improved significantly when treated with a medication called infliximab, which helped clear his symptoms and allowed him to reduce his steroid use. This is important because it shows that monoclonal antibodies targeting a specific factor in the immune system can be effective for patients who don't respond to standard treatments. Who this helps: This helps patients with severe Sweet syndrome and autoimmune conditions.

Plain English
This study looked at elderly cancer patients in intensive care units (ICUs) to understand their outcomes compared to younger patients. It found that many older patients do just as well in ICUs as younger ones and that age alone should not determine their care. Using the same indicators for recovery in elderly patients as in younger ones can lead to better care decisions without wasting resources. Who this helps: This helps elderly cancer patients and their doctors make informed decisions about ICU care.

Plain English
This study looked at how certain hormones, called gonadotropins, affect the production of a key immune protein known as interferon-gamma (IFN-gamma) from human blood cells. The researchers found that when gonadotropins were mixed with other substances that stimulate blood cells, the amount of IFN-gamma produced increased by four to eight times. This is important because stronger immune responses could help in treating infections or diseases where IFN-gamma plays a vital role. Who this helps: This research benefits patients needing enhanced immune responses, particularly those with infections or immune-related conditions.